Artiva Biotherapeutics

Artiva Biotherapeutics is a biotechnology company based in San Diego, California, specializing in the development of immunotherapy solutions. Currently a small team of one employee, Artiva Biotherapeutics has generated $50 million in revenue. The company focuses on producing off-the-shelf, allogeneic NK cell therapies, aiming to provide accessible and effective cell therapies for patients battling autoimmune diseases and cancers. Their flagship program, AlloNK®, is a novel allogeneic, non-genetically modified NK cell therapy designed to amplify the potency of monoclonal antibodies or NK cell engagers. AlloNK® is currently undergoing clinical trials for a range of applications. These include treating systemic lupus erythematosus (SLE) in patients with active lupus nephritis, Non-Hodgkin Lymphoma, and relapsed/refractory CD30-positive lymphomas, in combination with existing therapies like rituximab and Affimed’s innate cell engager AFM13. For further information on Artiva Biotherapeutics and its groundbreaking work, please visit their website at artivabio.com.